Cybin (CYBN) Stock Price & Analysis

CYBN$8.28+0.10 +1.22%
Biotechnology
Compare
Market cap$413.02MEnterprise value$358.16MRevenue (TTM)$0Market position—

Score

52
Neutral
Value
57
Quality
50
Growth
50

AI Analysis

Snapshot

Cybin is a mixed profile at 52/100 — Value 57, Growth 50, Quality 50. In Biotechnology, that score mix is usable but not one-dimensional.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

57
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

50
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

50
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Cybin Inc. (CYBN) last printed $8.28. Equity value is $413.02M. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

201720182019202020212022202320242025
$0.00$0.00$0.00$0.00$864,000.00$0.00$0.00$0.00$0.00

About

Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.

Cybin (CYBN) Stock Price & Analysis

CYBN price $8.28 +0.10 +1.22%

Ticker
CYBN
Price
$8.28
Change
+0.10 +1.22%
Market cap
$413.02M
Forward P/E
2.50
Dividend yield
0.00%
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
52
Value
57
Quality
50
Growth
50

Stocklytics score rationale: value 57, quality 50, growth 50.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener